Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04586920 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT04586920 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 104 participants.
The verdict
NCT04586920, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3509754 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3509754 gets into the bloodstream and how long it takes the body to eliminate it.
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG Itraconazole
- DRUG LY3509754
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2022-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04586920
The ClinicalTrials.gov registry entry for NCT04586920 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04586920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04586920 about?
NCT04586920 is a clinical study titled "A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants". The main purpose of this study in healthy participants is to learn more about the safety of LY3509754 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3509754 gets into the bloodstream and how long it takes the body to eliminate it.
What is the current status of trial NCT04586920?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2020-10-20. Estimated completion is 2022-10-14.
What interventions are being tested in trial NCT04586920?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), Itraconazole (DRUG), LY3509754 (DRUG).
Who is sponsoring clinical trial NCT04586920?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.